LZAGF - Lonza: Acceleration In Mid-Term Sales Growth

2024-04-04 13:20:24 ET

Summary

• Reflecting Lonza's Vacaville acquisition, we increased our sales and EBITDA expectations.
• The company has an ongoing buyback and a progressive dividend per share.
• We positively view the new CEO appointment. This removed an overhang of Lonza's equity story. Our buy is then confirmed.

Here at the Lab, following the latest positive news on Lonza Group AG ( OTCPK: LZAGY , LZAGF ), we are back to comment on the Swiss CDMO player. Worldwide, thousands of medical researchers work in labs to discover new treatments, and CDMO players (Contract Development and Manufacturing Organizations) provide comprehensive solutions to accelerate, develop, and manufacture life-changing therapies. For our new readers, the company engages its activities with four divisions: 1) Biologics, 2) Small Molecules, 3) Cell & Gene, and 4) Capsules & Health Ingredients....

For further details see: